Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > 7.4% growth & the 40% Gap in mineral production
View:
Post by biggdogg on Nov 22, 2024 9:50am

7.4% growth & the 40% Gap in mineral production

When the supply of iodine and barium minerals falls 40% short of the consumption growth for iodine and barium contrast media at a rate of 7.4%, it leads to escalating prices due to the imbalance. Voyageur is poised to take the lead in the contrast media sector, pending the inflationary pressures arising from this shortfall. The global iodine market, valued at USD 3.58 billion in 2023, is forecasted to expand by 4.4% annually from 2024 to 2030. Similarly, Superfine Precipitated Barium Sulphate is expected to experience a compound annual growth rate (CAGR) of 4.8% within the period of 2024 to 2030, reflecting the growing demand and the challenges of supply constraints in pharmaceutical contrast manufacturing. Add geopolitical instability, and this is a perfect storm for Voy, and its Earth to the Bottle strategy, is going to dominate this future market.

The global iodine market size was estimated at USD 3.58 billion in 2023 and is projected to grow at a CAGR of 4.4% from 2024 to 2030.
The global Superfine Precipitated Barium Sulphate a CAGR of 4.8% during the review period (2024-2030). 
https://www.openpr.com/news/3748799/superfine-precipitated-barium-sulphate-market-insights  https://www.grandviewresearch.com/industry-analysis/iodine-market-report
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1